Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization. CSL and Eli Lilly have struck a strategic ...

Abstract: Intelligent reflecting surface (IRS) is an enabling technology to engineer the radio signal propagation in wireless networks. By smartly tuning the signal reflection via a large number of ...

Purpose-built to optimise the production of plasma-derived therapies for conditions such as immunodeficiencies, neurological disorders, and burns, the Broadmeadows facility combines cutting-edge ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

CSL’s share slump following weak profits and a sudden CEO exit has pulled Australian healthcare stocks to multi-year lows, highlighting sector-wide concerns over regulation and investor sentiment. CSL ...

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category. The ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

The global biotechnology company announced minutes before the market closed on Tuesday that Mr McKenzie would be immediately replaced by Gordon Naylor, a current CSL director who has held a number of ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

MELBOURNE, Feb 11 (Reuters Breakingviews) - If anything screams despair, it's what CSL's (CSL.AX), opens new tab finance chief Ken Lim uttered on the $54 billion biotech company's Wednesday morning ...

Despite weaker-than-expected interim numbers, CSL maintains “ambitious” full-year guidance. But investors are sceptical Rhythm Biosciences enlists its first prescriber for its Colostat bowel cancer ...